References
[1] GBD 2015 Chronic Respiratory Disease Collaborators. (2017). Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Respiratory Medicine, 5(9), 691.
[2] Gayle, A.V., Minelli, C. & Quint, J.K. (2022). Respiratory-related death in individuals with incident asthma and COPD: a competing risk analysis. BMC Pulm Med., 22, 28 (2022). https://doi.org/10.1186/s12890-022-01823-4.
[3] Zeller, T. A., Beben, K., & Walker, S. (2023). Distinguishing Asthma and COPD in Primary Care: A Case-based Approach. American Family Physician, 107(3), 247-252.
[4] Efraij A., & FitzGerald J. (2015). Current and emerging treatments for severe asthma. Journal of Thoracic Disease, 7(11): E522-E525.
[5] Adeloye, D., Song, P., Zhu, Y., Campbell, H., Sheikh, A., & Rudan, I. (2022). Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. The Lancet Respiratory Medicine, 10(5), 447-458.
[6] World Health Organization. (2022). Chronic obstructive pulmonary disease (COPD). World Health Organization (WHO); 2020. Available from https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(COPD).
[7] Ihedike C, Mooney J, & Ling J. (2023). The Effect of PM10 and NOx on COPD and Asthma Patients in Abuja Nigeria. OAJRC Environmental Science, 4(1), 1-9.
[8] Wedzicha, J. A., & Donaldson, G. C. (2003). Exacerbations of chronic obstructive pulmonary disease. Respiratory care, 48(12), 1204-1215.
[9] Huang, H. P., Chen, K. H., Tsai, C. L., Chang, W. P., Chiu, S. Y., Lin, S. R., & Lin, Y. H. (2022). Effects of High-Frequency Chest Wall Oscillation on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International journal of chronic obstructive pulmonary disease, 17, 2857-2869. https://doi.org/10.2147/COPD.S378642.
[10] Basil G Bereza, Anders Troelsgaard Nielsen, Sverrir Valgardsson, Michiel EH Hemels, & Thomas R Einarson. (2015). Patient preferences in severe COPD and asthma: a comprehensive literature review. International Journal of Chronic Obstructive Pulmonary Disease, 10: 739-744, DOI: 10.2147/COPD.S82179.
[11] Viegi, G., Maio, S., Fasola, S., & Baldacci, S. (2020). Global Burden of Chronic Respiratory Diseases. Journal of aerosol medicine and pulmonary drug delivery, 33(4), 171-177. https://doi.org/10.1089/jamp.2019.1576.
[12] Hannah Collacott, Dian Zhang, Sebastian Heidenreich, Tommi Tervonen. (2022). A Systematic and Critical Review of Discrete Choice Experiments in Asthma and Chronic Obstructive Pulmonary Disease. The Patient -Patient-Centered Outcomes Research 15:1, pages 55-68.
[13] Gibson PG, Simpson JL (2009). The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax, 2009; 64:728-735.
[14] Rabe K. F. (2011). Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. British journal of pharmacology, 163(1), 53-67. https://doi.org/10.1111/j.1476-5381.2011.01218.x.
[15] Martínez-García, M.A., Perpiñá-Tordera, M., Román-Sánchez, P., & Soler-Cataluña, J.J. (2006). Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respiratory medicine, 100(9), 1623-32.
[16] Karbasi-Afshar, R., Aslani, J., & Ghanei, M. (2014). Efficacy and safety of inhaler steroids in COPD patients: Systematic review and meta-analysis of randomized placebo-controlled trials. Caspian journal of internal medicine, 5(3), 130-136.
[17] Shah, S. S., Ohlsson, A., Halliday, H. L., & Shah, V. S. (2017). Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. The Cochrane database of systematic reviews, 10(10), CD002058. https://doi.org/10.1002/14651858.CD002058.pub3.
[18] Beeh, K. M., & Beier, J. (2010). The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in therapy, 27(3), 150-159. https://doi.org/10.1007/s12325-010-0017-6.
[19] Lewis, A., Axson, E. L., Potts, J., Tarnowska, R., Vioix, H., & Quint, J. K. (2019). Protocol for a systematic literature review and network meta-analysis of the clinical benefit of inhaled maintenance therapies in chronic obstructive pulmonary disease. BMJ open, 9(2), e025048. https://doi.org/10.1136/bmjopen-2018-025048.
[20] Kiliç, L., Tural Önür, S., Gorek Dilektasli, A., Ulubay, G., & Balcı, A. (2023). Understanding the Impact of Pulmonary Rehabilitation on Airway Resistance in Patients with Severe COPD: A Single-Center Retrospective Study. International journal of chronic obstructive pulmonary disease, 18, 1-10. https://doi.org/10.2147/COPD.S384127.
[21] Jacobs J, Lisdonk E, I Smeele, C van Weel, & RPTM Grol. (2001). Management of patients with asthma and COPD: monitoring quality of life and the relationship to subsequent GP interventions. Family Practice, Volume 18, Issue 6, December 2001, Pages 574-580, https://doi.org/10.1093/fampra/18.6.574.
[22] Singh, D., Agusti, A., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Criner, G. J., Frith, P., Halpin, D. M. G., Han, M., López Varela, M. V., Martinez, F., Montes de Oca, M., Papi, A., Pavord, I. D., Roche, N., Sin, D. D., Stockley, R., Vestbo, J., Wedzicha, J. A., … Vogelmeier, C. (2019). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. The European Respiratory Journal, 53(5), 1900164.
https://doi.org/10.1183/13993003.00164-2019.